Milademetan + Milademetan
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumor
Conditions
Advanced Solid Tumor, Lymphoma
Trial Timeline
Jul 11, 2013 → Dec 3, 2020
NCT ID
NCT01877382About Milademetan + Milademetan
Milademetan + Milademetan is a phase 1 stage product being developed by Daiichi Sankyo for Advanced Solid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT01877382. Target conditions include Advanced Solid Tumor, Lymphoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumor were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01877382 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Solid Tumor